Alnylam Ends Relationship With Sirna Owner Merck
This article was originally published in The Pink Sheet Daily
Executive Summary
RNAi firm Alnylam terminated the relationship “to protect our intellectual property,” COO Greene tells “The Pink Sheet” DAILY.
You may also be interested in...
Regulus Signs Potential $600 Million MicroRNA Collaboration With GSK
Firms will co-develop microRNA targeted therapeutics in inflammation and immunology.
Regulus Signs Potential $600 Million MicroRNA Collaboration With GSK
Firms will co-develop microRNA targeted therapeutics in inflammation and immunology.
Alnylam Expands Asian Presence With RNAi License To Japan's GeneDesign
Alnylam Pharmaceuticals has granted Osaka, Japan-based GeneDesign a nonexclusive license to provide small interfering RNA research products and services using Alnylam's Kreutzer-Limmer patent estate, the companies announced Oct. 3